These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 30868230)

  • 1. Radiotherapy boost in patients with hypoxic lesions identified by
    Vera P; Mihailescu SD; Lequesne J; Modzelewski R; Bohn P; Hapdey S; Pépin LF; Dubray B; Chaumet-Riffaud P; Decazes P; Thureau S;
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1448-1456. PubMed ID: 30868230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II Study of a Radiotherapy Total Dose Increase in Hypoxic Lesions Identified by
    Vera P; Thureau S; Chaumet-Riffaud P; Modzelewski R; Bohn P; Vermandel M; Hapdey S; Pallardy A; Mahé MA; Lacombe M; Boisselier P; Guillemard S; Olivier P; Beckendorf V; Salem N; Charrier N; Chajon E; Devillers A; Aide N; Danhier S; Denis F; Muratet JP; Martin E; Riedinger AB; Kolesnikov-Gauthier H; Dansin E; Massabeau C; Courbon F; Farcy Jacquet MP; Kotzki PO; Houzard C; Mornex F; Vervueren L; Paumier A; Fernandez P; Salaun M; Dubray B
    J Nucl Med; 2017 Jul; 58(7):1045-1053. PubMed ID: 28254869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Hypermetabolic and Hypoxic Volumes Delineated on [
    Thureau S; Modzelewski R; Bohn P; Hapdey S; Gouel P; Dubray B; Vera P
    Mol Imaging Biol; 2020 Jun; 22(3):764-771. PubMed ID: 31432388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. To Explore a Representative Hypoxic Parameter to Predict the Treatment Response and Prognosis Obtained by [
    Li L; Wei Y; Huang Y; Yu Q; Liu W; Zhao S; Zheng J; Lu H; Yu J; Yuan S
    Mol Imaging Biol; 2018 Dec; 20(6):1061-1067. PubMed ID: 29623510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer.
    Thureau S; Dubray B; Modzelewski R; Bohn P; Hapdey S; Vincent S; Anger E; Gensanne D; Pirault N; Pierrick G; Vera P
    Radiat Oncol; 2018 Oct; 13(1):208. PubMed ID: 30352608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosimetry study of
    Li H; Xu D; Han X; Ruan Q; Zhang X; Mi Y; Dong M; Guo S; Lin Y; Wang B; Li G
    Clin Transl Oncol; 2018 Oct; 20(10):1329-1336. PubMed ID: 29623584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial.
    Nestle U; Schimek-Jasch T; Kremp S; Schaefer-Schuler A; Mix M; Küsters A; Tosch M; Hehr T; Eschmann SM; Bultel YP; Hass P; Fleckenstein J; Thieme A; Stockinger M; Dieckmann K; Miederer M; Holl G; Rischke HC; Gkika E; Adebahr S; König J; Grosu AL;
    Lancet Oncol; 2020 Apr; 21(4):581-592. PubMed ID: 32171429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
    J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma.
    McGowan DR; Skwarski M; Bradley KM; Campo L; Fenwick JD; Gleeson FV; Green M; Horne A; Maughan TS; McCole MG; Mohammed S; Muschel RJ; Ng SM; Panakis N; Prevo R; Strauss VY; Stuart R; Tacconi EMC; Vallis KA; McKenna WG; Macpherson RE; Higgins GS
    Eur J Cancer; 2019 May; 113():87-95. PubMed ID: 30991262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival.
    Everitt S; Ball D; Hicks RJ; Callahan J; Plumridge N; Trinh J; Herschtal A; Kron T; Mac Manus M
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):947-955. PubMed ID: 29063854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The predictive value of
    Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
    Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
    Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
    J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy.
    Eschmann SM; Paulsen F; Reimold M; Dittmann H; Welz S; Reischl G; Machulla HJ; Bares R
    J Nucl Med; 2005 Feb; 46(2):253-60. PubMed ID: 15695784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. F-18-FDG-PET confined radiotherapy of locally advanced NSCLC with concomitant chemotherapy: results of the PET-PLAN pilot trial.
    Fleckenstein J; Hellwig D; Kremp S; Grgic A; Gröschel A; Kirsch CM; Nestle U; Rübe C
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e283-9. PubMed ID: 21470782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic Analysis of Dynamic
    Schwartz J; Grkovski M; Rimner A; Schöder H; Zanzonico PB; Carlin SD; Staton KD; Humm JL; Nehmeh SA
    J Nucl Med; 2017 Jun; 58(6):911-919. PubMed ID: 28232611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of mediastinal tumor burden and lymphatic spread in locally advanced non-small-cell lung cancer: A secondary analysis of the multicenter randomized PET-Plan trial.
    Gkika E; Dejonckheere CS; Sahlmann J; Barth SA; Schimek-Jasch T; Adebahr S; Hecht M; Miederer M; Brose A; Binder H; König J; Grosu AL; Nestle U; Rimner A
    Radiother Oncol; 2024 Nov; 200():110521. PubMed ID: 39236984
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Qiu J; Lv B; Fu M; Wang X; Zheng X; Zhuo W
    Head Neck; 2017 Dec; 39(12):2519-2527. PubMed ID: 28963789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update of a Prospective Study of Stereotactic Body Radiation Therapy for Post-Chemoradiation Residual Disease in Stage II/III Non-Small Cell Lung Cancer.
    Kumar S; Feddock J; Li X; Shearer AJ; Hall L; Shelton BJ; Arnold S; McGarry RC
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(3):652-659. PubMed ID: 29280459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET.
    Cherk MH; Foo SS; Poon AM; Knight SR; Murone C; Papenfuss AT; Sachinidis JI; Saunder TH; O'Keefe GJ; Scott AM
    J Nucl Med; 2006 Dec; 47(12):1921-6. PubMed ID: 17138734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging of hypoxia with 18F-FAZA PET in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiotherapy.
    Trinkaus ME; Blum R; Rischin D; Callahan J; Bressel M; Segard T; Roselt P; Eu P; Binns D; MacManus MP; Ball D; Hicks RJ
    J Med Imaging Radiat Oncol; 2013 Aug; 57(4):475-81. PubMed ID: 23870348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.